<i>In Vivo</i> Mapping of Catecholaminergic Loss and Iron Deposition in Huntington's Disease
Our findings confirm widespread iron subcortical accumulation in HD, reveal significant noradrenergic neuronal loss, and describe dopaminergic alteration which may reflect ongoing pathology along the nigrostriatal pathway. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Authors
- Heather L. Wilson (ORCID: https://orcid.org/0000-0002-1261-0901)
- Georgia Karadima (ORCID: https://orcid.org/0000-0001-7003-5717)
- Athanasia Liozidou (ORCID: https://orcid.org/0000-0001-8895-819X)
- Edoardo Rosario de Natale (ORCID: https://orcid.org/0000-0002-9708-9886)
- Ioannis Zalonis
- Efstratios Karavasilis (ORCID: https://orcid.org/0000-0002-7291-2231)
- Georgios Velonakis (ORCID: https://orcid.org/0000-0002-0050-284X)
- Marios Politis
- Chrisoula Kartanou
- G. Koutsis
- Leonidas Stefanis
- Jens Kuhle
Institutions
- University of Basel (CH)
- National and Kapodistrian University of Athens (GR)
- University of Exeter (GB)
- University Hospital of Basel (CH)
- University General Hospital Attikon (GR)
- Eginition Hospital (GR)
Publication Details
- Journal
- Movement Disorders
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1002/mds.70221
- Primary Topic
- Genetic Neurodegenerative Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Michael J. Fox Foundation for Parkinson's Research
- Bristol-Myers Squibb
- AstraZeneca
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Alnylam Pharmaceuticals
- Celgene
- Universität Basel
- International Progressive MS Alliance
- Argenx
- National Research Foundation
- Genesis Pharma